Optimal HER2 testing

被引：0
|
作者：
Viale, Giuseppe [1 ,2 ]
机构：
[1] Univ Milan, Sch Med, Dept Pathol, Milan, Italy
[2] Univ Milan, Sch Med, European Inst Oncol, Milan, Italy
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(08)70306-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：31 / 32
页数：2
相关论文
共 50 条
  • [31] Using Protein Chips to Develop a Highly Specific HER2 Antibody for HER2 Amplification Testing
    Zhou, Lixin
    Yuan, Kehu
    Qi, Lili
    Li, Zhongwu
    Wu, Guiyin
    Huang, Xiaozheng
    Shen, Yi
    Zhao, Min
    Fu, Wei
    Liu, Huibo
    Chu, Boyang
    Wang, Guangli
    Shu, Youmin
    Ma, Donghui
    He, Weiwu
    Chen, Jian
    FASEB JOURNAL, 2015, 29
  • [32] HER2 Testing: Insights From Pathologists' Perspective on Technically Challenging HER2 FISH Cases
    Grimm, Erin, V
    Allison, Kimberly H.
    Hicks, David G.
    Swenson, Karen K.
    Krueger, Janet
    Yaziji, Hadi
    Downs-Kelly, Erinn
    Rendi, Mara H.
    Susnik, Barbara
    Tsai, Michaela L.
    Lillemoe, Tamera J.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (09) : 635 - 642
  • [33] Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
    Huang, Weidong
    Reinholz, Monica
    Weidler, Jodi
    Lie, Yolanda
    Paquet, Agnes
    Whitcomb, Jeannette
    Lingle, Wilma
    Jenkins, Robert B.
    Chen, Beiyun
    Larson, Jeffrey S.
    Tan, Yuping
    Sherwood, Thomas
    Bates, Michael
    Perez, Edith A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (02) : 303 - 311
  • [34] A Single-Center Experience with HER2 Testing and Low Level HER2 Expression in Endometrial Cancer
    Menshikova, Ekaterina
    Deeb, Kristin
    Genega, Elizabeth
    Wang, Qun
    Hanley, Krisztina
    Turashvili, Gulisa
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1210 - S1210
  • [35] Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy
    Yoshida, Hiroshi
    Nishikawa, Tadaaki
    Matsumoto, Koji
    Mori, Masahiko
    Hirashima, Yasuyuki
    Takehara, Kazuhiro
    Ariyoshi, Kazuya
    Hasegawa, Kosei
    Yonemori, Kan
    VIRCHOWS ARCHIV, 2021, 478 (06) : 1161 - 1171
  • [36] Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy
    Hiroshi Yoshida
    Tadaaki Nishikawa
    Koji Matsumoto
    Masahiko Mori
    Yasuyuki Hirashima
    Kazuhiro Takehara
    Kazuya Ariyoshi
    Kosei Hasegawa
    Kan Yonemori
    Virchows Archiv, 2021, 478 : 1161 - 1171
  • [37] Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
    Xu, Bin
    Shen, Jianguo
    Guo, Wenhao
    Zhao, Wenhe
    Zhuang, Yiyu
    Wang, Linbo
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (02) : 251 - 255
  • [38] Is HER2 overexpression sufficient for optimal response to Pertuzumab?
    Mehmet Ali Nahit Şendur
    Sercan Aksoy
    Şebnem Yaman
    Nuriye Yıldırım Özdemir
    Nurullah Zengin
    Medical Oncology, 2012, 29 : 2565 - 2566
  • [39] Is HER2 overexpression sufficient for optimal response to Pertuzumab?
    Sendur, Mehmet Ali Nahit
    Aksoy, Sercan
    Yaman, Sebnem
    Ozdemir, Nuriye Yildirim
    Zengin, Nurullah
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2565 - 2566
  • [40] Advances of HER2 testing for women with breast cancer
    Chivukula, Mamatha
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
12345